A Pittsburgh-based bioscience firm that specializes in oncology research announced it has undergone a rebranding effort as part of a plan to better align with the launch of its new platform.
SpIntellx, short for Spatial Biology leveraging Explainable AI (xAI) for predicting the progression of disease, will now go by PredxBio Inc., the same name as its platform that looks to improve drug discovery, translation and clinical trials with an initial focus in the immuno-oncology space.
"We are taking this critical step in our evolution as a spatial biology-based company to reflect the exciting capabilities we have developed leveraging unbiased spatial analytics and xAI to accelerate biomarker discovery, identify novel drug targets, and design better clinical trials identifying sub-populations of response with significantly greater precision," B. Dusty Majumdar, CEO of PredxBio, said in a prepared statement. "There is a critical need to lower costs and shorten the time it takes to develop cancer drugs for pharmaceutical companies, and we believe that the new PredxBio platform is uniquely poised to address these critical challenges head-on."
PredxBio said its new platform can integrate various types of data like spatial proteomics, spatial transcriptomics and brightfield pathology into one cohesive place, which the company said has the potential to reveal "the complex network biology of cancer." The platform has also been designed to render improved prediction accuracies as well, among other abilities.
